Drug Trial Radar · NCT01202188
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Sep 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,144
Actual
Start
Sep 2010
Primary completion
Feb 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149)Drug
Capsules for inhalation delivered via SDDPI.
glycopyrronium (NVA237)Drug
Capsules for inhalation delivered via SDDPI.
indacaterol (QAB149)Drug
Capsules for inhalation delivered via SDDPI.
tiotropiumDrug
Capsules for inhalation delivered via HandiHaler® device.
placeboDrug
Placebo to match capsules for inhalation delivered via SDDPI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of TreatmentTime frame: 23 hours 15 minutes and 23 hour 45 minute post-dose Week 26
Locations
166 sites in 19 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Troy, Michigan
Novartis Investigative Site
Minneapolis, Minnesota
Novartis Investigative Site
Saint Charles, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Medford, Oregon
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Greenville, South Carolina
Novartis Investigative Site
Johnson City, Tennessee
Novartis Investigative Site
Daw Park, Australia
Novartis Investigative Site
Glebe, Australia
Novartis Investigative Site
Kogarah, Australia
Novartis Investigative Site
Nedlands, Australia
Novartis Investigative site
New Lambton, Australia
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Rousse, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Burlington, Ontario, Canada
Novartis Investigative Site
Courtice, Ontario, Canada
Novartis Investigative Site
Mississuaga, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beuvry, France
Novartis Investigative Site
Bourges, France
Novartis Investigative Site
Ferolles-Attily, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Erfurt, Germany
Novartis Investigative Site
Geesthacht, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Leipzig, Germany
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.